A Study of a Novel Investigational Drug in Rheumatoid Arthritis Patients

This study is ongoing, but not recruiting participants.

Sponsored by:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00132769

Purpose

This study will look at whether this new drug is effective in the treatment of rheumatoid arthritis, and at whether it is safe and well-tolerated by patients with the disease.

This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).

Condition	Intervention	Phase
Rheumatoid Arthritis	Drug: MK-0873	Phase II

MedlinePlus related topics: Rheumatoid Arthritis

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Proprietary Information - Exploratory (Non-Confirmatory) Trial

Further study details as provided by Merck:

Primary Outcome Measures:

proprietary information - exploratory (non-confirmatory) trial

Secondary Outcome Measures:

proprietary information - exploratory (non-confirmatory) trial

Study Start Date:

January 2005

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Rheumatoid arthritis, according to the American College of Rheumatology criteria, with active disease despite current medications

Other criteria also apply.

Exclusion Criteria:

Other major illnesses
Past history of certain other disorders
Certain prohibited medications

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00132769

Sponsors and Collaborators

Merck

Investigators

Study Director:

Medical Monitor

Merck

More Information

Study ID Numbers:	2005_029
Study First Received:	August 2, 2005
Last Updated:	October 6, 2006
ClinicalTrials.gov Identifier:	NCT00132769
Health Authority:	Canada: Health Canada

Study placed in the following topic categories:

Autoimmune Diseases
Musculoskeletal Diseases
Joint Diseases
Arthritis

Connective Tissue Diseases
Arthritis, Rheumatoid
Rheumatic Diseases

Additional relevant MeSH terms:

Immune System Diseases

ClinicalTrials.gov processed this record on January 14, 2009